Active Metro Infusion Center Trials
Phase 2 clinical study is an adaptive, prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of WAL0921 in subjects with glomerular kidney diseases and proteinuria, including diabetic nephropathy (DN) and rare glomerular kidney diseases including focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), IgA nephropathy (IgAN) and membranous nephropathy (MN)
- A multi-center, randomized, double-blind, placebocontrolled, parallel group, phase Ill study to evaluate the efficacy and safety of LNP023 in primary lgA nephropathy patients
- A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg ofTrappsol'”‘Cyclo”‘ (Hydroxypropyl-P-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type CI
- Treatment Plan for ALS-Revexma™ #2201 Study
